MCL1 and hematologic disorder: PRT1419 is a potent and selective MCL1 inhibitor with anti-tumor efficacy in diverse preclinical models of solid and hematologic malignancies, which is currently being evaluated in a Phase 1 clinical trial (NCT05107856).